FluoGuide A/S (STO:FLUO)

Sweden flag Sweden · Delayed Price · Currency is SEK
35.80
-0.10 (-0.28%)
At close: Feb 27, 2026
-21.83%
Market Cap 585.31M
Revenue (ttm) 318.79K
Net Income (ttm) -57.18M
Shares Out 16.35M
EPS (ttm) -4.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,453
Average Volume 6,982
Open 34.20
Previous Close 35.90
Day's Range 34.20 - 37.30
52-Week Range 29.10 - 48.00
Beta 0.37
RSI 54.43
Earnings Date Feb 25, 2026

About FluoGuide

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol FLUO
Full Company Profile

Financial Performance

In 2025, FluoGuide's revenue was 220,000, a decrease of -42.86% compared to the previous year's 385,000. Losses were -39.46 million, 36.3% more than in 2024.

Financial numbers in DKK Financial Statements

News

There is no news available yet.